710 Keynote-B59: dose escalation of a phase 1/2 first-in-human, open-label study of GI-101, a novel immunocytokine combining CD80-IL2v, in combination with pembrolizumab in advanced solid tumors

710 Keynote-B59: dose escalation of a phase 1/2 first-in-human, open-label study of GI-101, a novel immunocytokine combining CD80-IL2v, in combination with pembrolizumab in advanced solid tumors

Bibliographic Details
Main Authors: John Powderly, Jae Lyun Lee, Jung-Yun Lee, Byoung Chul Cho, Kyoung-Ho Pyo, Soohyeon Lee, Dong Kim, Myoung Ho Jang, Byoung Yong Shim, Sang Joon Shin, Nari Yun, Mina Ham, Julia Cohen, Hyo Jin Lee, Kyoyoung Lee, Hyunjin Kang, Jea Hwan Kim, Mi hyun Kim
Format: Article
Language:English
Published: BMJ Publishing Group 2023-11-01
Series:Journal for ImmunoTherapy of Cancer

Similar Items